Hemab Therapeutics Holdings, Inc. (COAG)
39.40
-0.48
(-1.20%)
USD |
NASDAQ |
Sep 11, 16:00
39.47
+0.07
(+0.18%)
After-Hours: 20:00
Hemab Therapeutics Holdings Enterprise Value : 1.384B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 1.384B |
| September 10, 2026 | 1.406B |
| September 09, 2026 | 1.622B |
| September 08, 2026 | 1.625B |
| September 04, 2026 | 1.618B |
| September 03, 2026 | 1.616B |
| September 02, 2026 | 1.631B |
| September 01, 2026 | 1.600B |
| August 31, 2026 | 1.679B |
| August 28, 2026 | 1.638B |
| August 27, 2026 | 1.855B |
| August 26, 2026 | 1.841B |
| August 25, 2026 | 1.862B |
| August 24, 2026 | 1.723B |
| August 21, 2026 | 1.840B |
| August 20, 2026 | 1.795B |
| August 19, 2026 | 1.956B |
| August 18, 2026 | 1.993B |
| August 17, 2026 | 2.047B |
| August 14, 2026 | 2.110B |
| August 13, 2026 | 2.063B |
| August 12, 2026 | 2.041B |
| August 11, 2026 | 1.960B |
| August 10, 2026 | 1.873B |
| August 07, 2026 | 1.863B |
| Date | Value |
|---|---|
| August 06, 2026 | 1.980B |
| August 05, 2026 | 1.883B |
| August 04, 2026 | 1.716B |
| August 03, 2026 | 1.645B |
| July 31, 2026 | 1.764B |
| July 30, 2026 | 1.761B |
| July 29, 2026 | 1.634B |
| July 28, 2026 | 1.751B |
| July 27, 2026 | 1.897B |
| July 24, 2026 | 1.753B |
| July 23, 2026 | 1.684B |
| July 22, 2026 | 1.843B |
| July 21, 2026 | 1.799B |
| July 20, 2026 | 1.850B |
| July 17, 2026 | 1.846B |
| July 16, 2026 | 1.623B |
| July 15, 2026 | 1.567B |
| July 14, 2026 | 1.566B |
| July 13, 2026 | 1.389B |
| July 10, 2026 | 1.320B |
| July 09, 2026 | 1.281B |
| July 08, 2026 | 1.126B |
| July 07, 2026 | 1.014B |
| July 06, 2026 | 943.33M |
| July 02, 2026 | 991.43M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Apogee Therapeutics, Inc. | 9.310B |
| Arrowhead Pharmaceuticals, Inc. | 11.47B |
| Oncolytics Biotech, Inc. | 89.25M |
| Sangamo Therapeutics, Inc. | 53.27M |
| Sarepta Therapeutics, Inc. | 2.417B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.15M |
| Total Expenses (Quarterly) | 24.15M |
| EPS Diluted (Quarterly) | -0.5171 |
| Earnings Yield | -4.04% |
| Normalized Earnings Yield | -4.040 |